DSS, INC. DSS Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0001641172-25-010712
cik 771999
name DSS, INC.
sic 2650
countryba US
stprba NY
cityba WEST HENRIETTA
zipba 14586
bas1 275 WIREGRASS PKWY
bas2
baph 585 232 1500
countryma US
stprma NY
cityma WEST HENRIETTA
zipma 14586
mas1 275 WIREGRASS PKWY
mas2
countryinc US
stprinc NY
ein 161229730
former DOCUMENT SECURITY SYSTEMS INC
changed 20030326
afs 4-NON
wksi 0
fye 1231
form 10-Q
period 20250331
fy 2025
fp Q1
filed 20250515
accepted 2025-05-15 14:07:00.0
prevrpt 0
detail 1
instance form10-q_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001641172-25-010712 20241231 Assets 106453000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Accounts Receivable Net Current 2627000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Accrued Expenses And Deferred Revenue Current 2290000.0000 USD 0 0001641172-25-010712
0001641172-25-010712 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 6615000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Commitments And Contingencies USD 0 us-gaap/2024
0001641172-25-010712 20250331 Commitments And Contingencies 0.0000 USD 0 us-gaap/2024 Type Of Arrangement= License Agreement;
0001641172-25-010712 20231031 Common Stock Shares Authorized 60496041.0000 shares 0 us-gaap/2024 Class Of Stock= Series A Convertible Preferred Stock; Legal Entity= D S S Bio Health Securities Inc;
0001641172-25-010712 20240930 Common Stock Shares Outstanding 11503955.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20250331 Common Stock Value 182000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Current Portion Of Longterm Debt On Assets Heldforsale Net 45794000.0000 USD 0 0001641172-25-010712
0001641172-25-010712 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -5084000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -1788000.0000 USD 1 us-gaap/2024 Business Segments= Corporate; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Income Tax Expense Benefit 25000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Increase Decrease Assets Held For Sale 32000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Interest Expense 33000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Inventory Net 2499000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Issuance Of Common Stock Net Of Expenses To Subsidiary 1499000.0000 USD 1 0001641172-25-010712 Equity Components= Additional Paid In Capital;
0001641172-25-010712 20241231 Liabilities And Stockholders Equity 106453000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Long Term Debt Current 520000.0000 USD 0 us-gaap/2024 Legal Entity= Premier Packaging Bank Of America N A; PremierPackagingBankOfAmericaNA
0001641172-25-010712 20250331 Long Term Debt Noncurrent 2398000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Minority Interest 12477000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Net Income Loss Attributable To Noncontrolling Interest -519000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Net Income Loss Available To Common Stockholders Basic -4777000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20241231 Notes And Loans Receivable Net Current 450000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Fourteen;
0001641172-25-010712 20241231 Notes And Loans Receivable Net Noncurrent 17000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-010712 20241231 Notes And Loans Receivable Net Noncurrent 135000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Thirteen;
0001641172-25-010712 20250331 Notes And Loans Receivable Net Noncurrent 18000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Five;
0001641172-25-010712 20250331 Notes And Loans Receivable Net Noncurrent 66000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Fourteen;
0001641172-25-010712 20250331 Operating Expenses 1057000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Income Loss -23000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Income Loss -512000.0000 USD 1 us-gaap/2024 Business Segments= Product Packaging; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Lease Liability Current 584000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Other Assets Noncurrent 162000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Other Liabilities Current 4193000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Other Nonoperating Income Expense -158000.0000 USD 1 us-gaap/2024 Business Segments= Securities; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Other Nonoperating Income Expense -247000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending; Consolidation Items= Operating Segments;
0001641172-25-010712 20240930 Preferred Stock Shares Issued 60496041.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20250331 Proceed From Sale Of Real Estate 9500000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20240331 Proceeds From Sale Of Investment Related Party USD 1 0001641172-25-010712
0001641172-25-010712 20240331 Profit Loss USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-010712 20240331 Profit Loss -1037000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001641172-25-010712 20250331 Profit Loss USD 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20250331 Profit Loss -4777000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0001641172-25-010712 20250331 Repayments On Margin Loans 2806000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20241231 Restricted Cash Current USD 0 us-gaap/2024
0001641172-25-010712 20250331 Retained Earnings Accumulated Deficit -307849000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 2000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax USD 1 us-gaap/2024 Business Segments= Corporate; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 400000.0000 USD 1 us-gaap/2024 Product Or Service= Rental Income;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 920000.0000 USD 1 us-gaap/2024 Business Segments= Securities; Consolidation Items= Operating Segments;
0001641172-25-010712 20231231 Shares Outstanding 7067772.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20231231 Shares Outstanding shares 0 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20241231 Shares Outstanding shares 0 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 140000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 319963000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-010712 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 325530000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-010712 20250331 Stock Issued During Period Shares Issued For Services 36433.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20250331 Stock Issued During Period Shares Other 963567.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20250331 Stock Issued During Period Value Issued For Services USD 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20250331 Stock Issued During Period Value Other 20000.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20240331 Weighted Average Number Of Shares Outstanding Basic 7066772.0000 shares 1 us-gaap/2024
0001641172-25-010712 20250331 Weighted Average Number Of Shares Outstanding Basic 8685925.0000 shares 1 us-gaap/2024
0001641172-25-010712 20241231 Assets Current 63817000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Assets Current 52822000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 11431000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 10975000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 2637000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Common Stock Shares Authorized 200000000.0000 shares 0 us-gaap/2024
0001641172-25-010712 20231231 Common Stock Shares Issued 140264240.0000 shares 0 us-gaap/2024
0001641172-25-010712 20241231 Common Stock Shares Outstanding 8092518.0000 shares 0 us-gaap/2024
0001641172-25-010712 20241231 Common Stock Value 161000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Depreciation And Amortization 582000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Depreciation And Amortization 523000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Equity Method Investments Gain Loss -3000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Impairment Of Notes Receivable USD 1 0001641172-25-010712
0001641172-25-010712 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -69000.0000 USD 1 us-gaap/2024 Business Segments= Direct Marketing Online Sales; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Income Loss From Equity Method Investments -3000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Increase Decrease In Accounts Payable -362000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Increase Decrease In Inventories 36000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Increase Decrease In Operating Lease Liability -167000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Interest Expense 48000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Investment Income Interest 107000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Issuance Of Common Stock Net Of Expenses To Subsidiary USD 1 0001641172-25-010712 Equity Components= Noncontrolling Interest;
0001641172-25-010712 20250331 Issuance Of Common Stock Net Of Expenses To Subsidiary 1500000.0000 USD 1 0001641172-25-010712 Equity Components= Parent;
0001641172-25-010712 20241231 Liabilities Current 65028000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Long Term Debt Current 125000.0000 USD 0 us-gaap/2024 Type Of Arrangement= Security Agreement;
0001641172-25-010712 20250331 Minority Interest 11958000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Net Income Loss Available To Common Stockholders Basic -4072000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20241231 Notes And Loans Receivable Net Current 240000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-010712 20241231 Notes And Loans Receivable Net Current 5544000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note One;
0001641172-25-010712 20241231 Notes And Loans Receivable Net Current 884000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Three;
0001641172-25-010712 20241231 Notes And Loans Receivable Net Noncurrent 17000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Five;
0001641172-25-010712 20250331 Operating Expenses 1466000.0000 USD 1 us-gaap/2024 Business Segments= Corporate; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Operating Income Loss -4680000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Operating Income Loss -2181000.0000 USD 1 us-gaap/2024 Business Segments= Securities; Consolidation Items= Operating Segments;
0001641172-25-010712 20241231 Operating Lease Right Of Use Asset 6465000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Operating Lease Right Of Use Asset 6288000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Other Assets Noncurrent 579000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Other Nonoperating Income Expense -322000.0000 USD 1 us-gaap/2024 Business Segments= Corporate; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Payments To Acquire Property Plant And Equipment 52000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Preferred Stock Par Or Stated Value Per Share 0.0200 USD 0 us-gaap/2024
0001641172-25-010712 20240930 Preferred Stock Shares Outstanding 60496041.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20241231 Preferred Stock Value USD 0 us-gaap/2024
0001641172-25-010712 20250331 Prepaid Expense And Other Assets Current 741000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Proceeds From Repayment Of Investments -1000000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Proceeds From Sale Of Investment Related Party 1500000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Proceeds From Sale Of Notes Receivable 122000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Profit Loss -4072000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-010712 20211031 Property Plant And Equipment Net 24722000.0000 USD 0 us-gaap/2024 Legal Entity= Pinnacle Bank; Type Of Arrangement= Life Care Agreement;
0001641172-25-010712 20240930 Property Plant And Equipment Net 4396000.0000 USD 0 us-gaap/2024 Debt Instrument= Pinnacle Loan;
0001641172-25-010712 20241231 Property Plant And Equipment Net 6332000.0000 USD 0 us-gaap/2024 Legal Entity= A M R E Shelton L L C; Type Of Arrangement= Loan Agreement;
0001641172-25-010712 20240331 Provision For Loan Losses -294000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Provision For Loan Loss Recoveries 21000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Repayments Of Long Term Debt 8997000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Restricted Cash Current 143000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 3871000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax USD 1 us-gaap/2024 Business Segments= Direct Marketing Online Sales; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 2882000.0000 USD 1 us-gaap/2024 Business Segments= Packaging Printingand Fabrication; Product Or Service= Printed Products Revenue;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 303000.0000 USD 1 us-gaap/2024 Business Segments= Securities Revenue; Product Or Service= Commission Income;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 384000.0000 USD 1 us-gaap/2024 Business Segments= Securities Revenue; Product Or Service= Rental Income;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 303000.0000 USD 1 us-gaap/2024 Product Or Service= Commission Revenue;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 21000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 920000.0000 USD 1 us-gaap/2024 Product Or Service= Securities Revenue;
0001641172-25-010712 20250331 Selling General And Administrative Expense 3493000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Shares Outstanding shares 0 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20241231 Shares Outstanding 8092518.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20240331 Stock Based Payments For Professional Services USD 1 0001641172-25-010712
0001641172-25-010712 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest USD 0 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 59855000.0000 USD 0 us-gaap/2024 Equity Components= Parent;
0001641172-25-010712 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest USD 0 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 323150000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-010712 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 11958000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001641172-25-010712 20250331 Stock Issued During Period Value Issued For Services USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001641172-25-010712 20250331 Stock Issued During Period Value Issued For Services 29000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0001641172-25-010712 20250331 Stock Issued During Period Value Other 870000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0001641172-25-010712 20250331 Stock Issued During Period Value Other USD 1 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20250331 Increase Decrease In Operating Lease Liability -165000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20241231 Additional Paid In Capital 323150000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Additional Paid In Capital 325530000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Cash And Cash Equivalents At Carrying Value 11431000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Change In Inventory Obsolescence USD 1 0001641172-25-010712
0001641172-25-010712 20230430 Common Stock Shares Authorized 125073621.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; Scenario= Prior To Split;
0001641172-25-010712 20231231 Common Stock Shares Issued 3877282251.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical; ImpactBioMedical
0001641172-25-010712 20241231 Current Portion Of Longterm Debt On Assets Heldforsale Net 53534000.0000 USD 0 0001641172-25-010712
0001641172-25-010712 20240331 Equity Method Investments Gain Loss -1000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -1383000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -2339000.0000 USD 1 us-gaap/2024 Business Segments= Securities; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -1715000.0000 USD 1 us-gaap/2024 Business Segments= Securities; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Increase Decrease In Other Operating Liabilities 471000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Interest Expense 13000.0000 USD 1 us-gaap/2024 Type Of Arrangement= Security Agreement;
0001641172-25-010712 20250331 Liabilities Current 54048000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Long Term Debt Current 642000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-010712 20241231 Long Term Debt Current 609000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-010712 20250331 Marketable Securities Noncurrent 6480000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Net Cash Provided By Used In Financing Activities -11694000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Operating Costs And Expenses 4990000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Operating Expenses 8551000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Operating Expenses 736000.0000 USD 1 us-gaap/2024 Business Segments= Corporate; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Operating Income Loss -811000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Operating Income Loss -411000.0000 USD 1 us-gaap/2024 Business Segments= Product Packaging; Consolidation Items= Operating Segments;
0001641172-25-010712 20241231 Operating Lease Liability Noncurrent 6311000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Other Nonoperating Income Expense 41000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Consolidation Items= Operating Segments;
0001641172-25-010712 20220331 Payments To Acquire Property Plant And Equipment 222000.0000 USD 0 us-gaap/2024 Debt Instrument= Pinnacle Loan; Property Plant And Equipment By Type= Site And Tenant Improvements;
0001641172-25-010712 20231231 Preferred Stock Shares Outstanding 60496041.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001641172-25-010712 20250331 Profit Loss -519000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001641172-25-010712 20250331 Property Plant And Equipment Net 5238000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Provision For Loan Losses USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Real Estate Assets Held For Development And Sale 35440000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Retained Earnings Accumulated Deficit -303072000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 15000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 15000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Product Or Service= Rental Internet Sales;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax USD 1 us-gaap/2024 Business Segments= Corporate; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Share Based Compensation USD 1 us-gaap/2024
0001641172-25-010712 20250331 Share Based Compensation 2000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 19286000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001641172-25-010712 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 12477000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001641172-25-010712 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 20239000.0000 USD 0 us-gaap/2024 Equity Components= Parent;
0001641172-25-010712 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 182000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -307849000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-010712 20250131 Stock Issued During Period Shares Issued For Services 1000000.0000 shares 0 us-gaap/2024 Plan Name= Equity Incentive Plan;
0001641172-25-010712 20250331 Stock Issued During Period Value Other USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-010712 20250331 Weighted Average Number Of Diluted Shares Outstanding 8685925.0000 shares 1 us-gaap/2024
0001641172-25-010712 20240331 Income Loss From Equity Method Investments -1000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Increase Decrease In Accrued Liabilities -364000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Increase Decrease In Other Operating Assets 417000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Interest Expense 71000.0000 USD 1 us-gaap/2024 Debt Instrument= Pinnacle Loan;
0001641172-25-010712 20250331 Issuance Of Common Stock Net Of Expenses To Subsidiary USD 1 0001641172-25-010712 Equity Components= Preferred Stock;
0001641172-25-010712 20250331 Liabilities 62614000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20210731 Long Term Debt Current 5105000.0000 USD 0 us-gaap/2024 Legal Entity= A M R E Shelton L L C; Type Of Arrangement= Loan Agreement;
0001641172-25-010712 20241231 Long Term Debt Current 123000.0000 USD 0 us-gaap/2024 Type Of Arrangement= Security Agreement;
0001641172-25-010712 20241231 Notes And Loans Receivable Net Current 337000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-010712 20241231 Notes And Loans Receivable Net Current 184000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Eleven;
0001641172-25-010712 20241231 Notes And Loans Receivable Net Current 224000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Seven;
0001641172-25-010712 20250331 Notes And Loans Receivable Net Current 284000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-010712 20240331 Operating Expenses 803000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Operating Expenses 114000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Operating Income Loss -736000.0000 USD 1 us-gaap/2024 Business Segments= Corporate; Consolidation Items= Operating Segments;
0001641172-25-010712 20241231 Operating Lease Liability Current 606000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Other Liabilities Current 1858000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Payments To Acquire Property Plant And Equipment 3000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20241231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001641172-25-010712 20240331 Proceed From Sale Of Real Estate USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Property Plant And Equipment Net 6332000.0000 USD 0 us-gaap/2024 Legal Entity= A M R E Shelton L L C; Type Of Arrangement= Loan Agreement;
0001641172-25-010712 20241231 Real Estate Assets Held For Development And Sale 45158000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Repayments Of Long Term Debt 1062000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 102000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 102000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending Revenue; Product Or Service= Net Investment Income;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 2000.0000 USD 1 us-gaap/2024 Product Or Service= Direct Markeing;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 102000.0000 USD 1 us-gaap/2024 Product Or Service= Net Investment Revenue Income;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 15000.0000 USD 1 us-gaap/2024 Product Or Service= Biotechnology Marketing;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 3998000.0000 USD 1 us-gaap/2024 Product Or Service= Printed Products;
0001641172-25-010712 20250331 Stockholders Equity 17863000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -260248000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-010712 20250331 Stock Issued During Period Shares Share Based Compensation shares 1 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20250331 Stock Issued During Period Value Issued For Services USD 1 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20250331 Stock Issued During Period Value Other USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001641172-25-010712 20250331 Cash And Cash Equivalents At Carrying Value 10832000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 9252000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0001641172-25-010712 20231231 Common Stock Shares Issued 10000000.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20250331 Equity Method Investments 126000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Gains Losses On Sales Of Real Estate -684000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -941000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Increase Decrease In Accounts Receivable -1347000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -27000.0000 USD 1 us-gaap/2024 Business Segments= Direct Marketing Online Sales; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -551000.0000 USD 1 us-gaap/2024 Business Segments= Product Packaging; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -5363000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Increase Decrease Assets Held For Sale USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Increase Decrease In Accounts Receivable -441000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Increase Decrease In Accrued Liabilities 489000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Increase Decrease In Other Operating Assets 36000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets -36000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Interest Expense 867000.0000 USD 1 us-gaap/2024 Legal Entity= Pinnacle Bank; Type Of Arrangement= Life Care Agreement;
0001641172-25-010712 20250331 Interest Expense 11000.0000 USD 1 us-gaap/2024 Type Of Arrangement= Security Agreement;
0001641172-25-010712 20250331 Issuance Of Common Stock Net Of Expenses To Subsidiary 1000.0000 USD 1 0001641172-25-010712 Equity Components= Common Stock;
0001641172-25-010712 20240331 Net Cash Provided By Used In Financing Activities -310000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Net Cash Provided By Used In Investing Activities 5097000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Net Cash Provided By Used In Investing Activities 12876000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Net Cash Provided By Used In Operating Activities -2150000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20231130 Notes And Loans Receivable Net Current 50000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Four;
0001641172-25-010712 20250331 Notes And Loans Receivable Net Current 256000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-010712 20250331 Notes And Loans Receivable Net Current 350000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Fourteen;
0001641172-25-010712 20250331 Notes And Loans Receivable Net Current 224000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Seven;
0001641172-25-010712 20241231 Notes And Loans Receivable Net Noncurrent 112000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-010712 20240331 Operating Expenses 724000.0000 USD 1 us-gaap/2024 Business Segments= Product Packaging; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Expenses 709000.0000 USD 1 us-gaap/2024 Business Segments= Product Packaging; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Income Loss -34000.0000 USD 1 us-gaap/2024 Business Segments= Direct Marketing Online Sales; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Other Intangible Assets Net 18567000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Other Investments 500000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Other Nonoperating Income Expense 842000.0000 USD 1 us-gaap/2024 Business Segments= Corporate; Consolidation Items= Operating Segments;
0001641172-25-010712 20241231 Preferred Stock Liquidation Preference Value 0.0000 USD 0 us-gaap/2024
0001641172-25-010712 20231231 Preferred Stock Shares Issued 60496041.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20250331 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001641172-25-010712 20240331 Proceeds From Sale And Maturity Of Marketable Securities 1160000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Real Estate Assets Held For Development And Sale 24722000.0000 USD 0 us-gaap/2024 Legal Entity= A M R E Life Care Portfolio L L C; AMRELifeCarePortfolioLLC
0001641172-25-010712 20250331 Real Estate Assets Held For Development And Sale 4396000.0000 USD 0 us-gaap/2024 Legal Entity= A M R E Winter Haven L L C; AMREWinterHavenLLC
0001641172-25-010712 20240331 Repayments On Margin Loans USD 1 0001641172-25-010712
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 198000.0000 USD 1 us-gaap/2024 Business Segments= Commercialand Security Printing; Product Or Service= Printed Products Revenue;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 687000.0000 USD 1 us-gaap/2024 Business Segments= Securities; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 95000.0000 USD 1 us-gaap/2024 Product Or Service= Net Investment Income;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 4954000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax USD 1 us-gaap/2024 Business Segments= Direct Marketing Online Sales; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 221000.0000 USD 1 us-gaap/2024 Product Or Service= Commission Revenue;
0001641172-25-010712 20250331 Shares Outstanding shares 0 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20241231 Stockholders Equity 20239000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 319963000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-010712 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 78104000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 161000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 17863000.0000 USD 0 us-gaap/2024 Equity Components= Parent;
0001641172-25-010712 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest USD 0 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20250331 Stock Issued During Period Shares Share Based Compensation 2000.0000 shares 1 us-gaap/2024
0001641172-25-010712 20250331 Stock Issued During Period Shares Share Based Compensation 2000.0000 shares 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-010712 20250331 Stock Issued During Period Shares Share Based Compensation shares 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001641172-25-010712 20250331 Stock Issued During Period Shares Share Based Compensation shares 1 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-010712 20250131 Stock Issued During Period Value Issued For Services 870000.0000 USD 0 us-gaap/2024 Plan Name= Equity Incentive Plan;
0001641172-25-010712 20250331 Stock Issued During Period Value Issued For Services USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-010712 20240930 Common Stock Shares Outstanding 11497703.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical; Subsidiary Sale Of Stock= I P O;
0001641172-25-010712 20250331 Gain Loss On Investments -930000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20241231 Accounts Payable Current 2793000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Change In Inventory Obsolescence 21000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Change In Right Of Use Assets -177000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20230430 Common Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20240930 Common Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2024 Legal Entity= Impact Bio Medical; Subsidiary Sale Of Stock= I P O;
0001641172-25-010712 20250331 Common Stock Par Or Stated Value Per Share 0.0200 USD 0 us-gaap/2024
0001641172-25-010712 20240930 Common Stock Shares Issued 11497703.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical; Subsidiary Sale Of Stock= I P O;
0001641172-25-010712 20240331 Gain Loss On Sale Of Investments -189000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Gain Loss On Sale Of Investments -925000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Goodwill 1769000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Impairment Of Notes Receivable 763000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 106000.0000 USD 1 us-gaap/2024 Business Segments= Corporate; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Income Tax Expense Benefit -67000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Increase Decrease In Inventories 808000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets -400000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Interest Expense 38000.0000 USD 1 us-gaap/2024 Debt Instrument= Pinnacle Loan;
0001641172-25-010712 20241231 Interest Expense 977000.0000 USD 4 us-gaap/2024 Legal Entity= Pinnacle Bank; Type Of Arrangement= Life Care Agreement;
0001641172-25-010712 20250331 Investment Income Interest 9000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Long Term Debt Current 526000.0000 USD 0 us-gaap/2024 Legal Entity= Premier Packaging Bank Of America N A; PremierPackagingBankOfAmericaNA
0001641172-25-010712 20250331 Long Term Debt Current 606000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-010712 20250331 Notes And Loans Receivable Net Noncurrent USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-010712 20250331 Operating Costs And Expenses 5187000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Operating Expenses 60000.0000 USD 1 us-gaap/2024 Business Segments= Direct Marketing Online Sales; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Operating Expenses 3561000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Expenses 65000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Income Loss -1053000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Income Loss -1466000.0000 USD 1 us-gaap/2024 Business Segments= Corporate; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Income Loss -3726000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Other Nonoperating Income Expense -130000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Other Nonoperating Income Expense -47000.0000 USD 1 us-gaap/2024 Business Segments= Product Packaging; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Other Nonoperating Income Expense -404000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Other Nonoperating Income Expense -39000.0000 USD 1 us-gaap/2024 Business Segments= Product Packaging; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Other Nonoperating Income Expense -1637000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001641172-25-010712 20210731 Payments To Acquire Property Plant And Equipment 4640000.0000 USD 0 us-gaap/2024 Legal Entity= A M R E Shelton L L C; Property Plant And Equipment By Type= Facility; Type Of Arrangement= Loan Agreement;
0001641172-25-010712 20210731 Payments To Acquire Property Plant And Equipment 1600000.0000 USD 0 us-gaap/2024 Legal Entity= A M R E Shelton L L C; Property Plant And Equipment By Type= Land; Type Of Arrangement= Loan Agreement;
0001641172-25-010712 20210731 Payments To Acquire Property Plant And Equipment 325000.0000 USD 0 us-gaap/2024 Legal Entity= A M R E Shelton L L C; Property Plant And Equipment By Type= Tenant Improvements; Type Of Arrangement= Loan Agreement;
0001641172-25-010712 20211031 Payments To Acquire Property Plant And Equipment 12100000.0000 USD 0 us-gaap/2024 Legal Entity= Pinnacle Bank; Property Plant And Equipment By Type= Land; Type Of Arrangement= Life Care Agreement;
0001641172-25-010712 20241231 Preferred Stock Liquidation Preference 1000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Preferred Stock Shares Authorized 47000.0000 shares 0 us-gaap/2024
0001641172-25-010712 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001641172-25-010712 20240331 Proceeds From Issuance Of Long Term Debt 752000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Profit Loss USD 1 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20240331 Provision For Loan Loss Recoveries USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Real Estate Assets Held For Development And Sale 6322000.0000 USD 0 us-gaap/2024 Legal Entity= A M R E Shelton L L C; AMRESheltonLLC
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 3080000.0000 USD 1 us-gaap/2024 Product Or Service= Printed Products Revenue;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 687000.0000 USD 1 us-gaap/2024 Product Or Service= Securities Revenue;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 21000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending Revenue; Product Or Service= Net Investment Income;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 3863000.0000 USD 1 us-gaap/2024 Business Segments= Packaging Printingand Fabrication; Product Or Service= Printed Products Revenue;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 3998000.0000 USD 1 us-gaap/2024 Business Segments= Product Packaging; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 21000.0000 USD 1 us-gaap/2024 Product Or Service= Net Investment Income;
0001641172-25-010712 20240331 Shares Outstanding 7067772.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 140000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -303072000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-010712 20250331 Stock Issued During Period Shares Share Based Compensation 2000.0000 shares 1 us-gaap/2024 Equity Components= Parent;
0001641172-25-010712 20250331 Stock Issued During Period Value Issued For Services 29000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Stock Issued During Period Value Issued For Services 29000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-010712 20241231 Accrued Expenses And Deferred Revenue Current 2651000.0000 USD 0 0001641172-25-010712
0001641172-25-010712 20240331 Change In Right Of Use Assets -184000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20241231 Common Stock Shares Authorized 200000000.0000 shares 0 us-gaap/2024
0001641172-25-010712 20221231 Common Stock Shares Outstanding 3877282251.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical; ImpactBioMedical
0001641172-25-010712 20231231 Common Stock Shares Outstanding 3877282251.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical; ImpactBioMedical
0001641172-25-010712 20240331 Gains Losses On Sales Of Real Estate USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -5363000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -1012000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Income Loss From Discontinued Operations Net Of Tax Per Diluted Share -0.5800 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Income Loss From Discontinued Operations Net Of Tax Per Diluted Share -0.5500 USD 1 us-gaap/2024
0001641172-25-010712 20241231 Inventory Net 2442000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Issuance Of Common Stock For Bonus USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Issuance Of Common Stock For Bonus 870000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20241231 Liabilities 73737000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Liabilities And Stockholders Equity 92435000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Net Income Loss Attributable To Noncontrolling Interest -1037000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Notes And Loans Receivable Net Current 200000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Eleven;
0001641172-25-010712 20250331 Notes And Loans Receivable Net Current 884000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Three;
0001641172-25-010712 20241231 Notes And Loans Receivable Net Noncurrent 113000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Fourteen;
0001641172-25-010712 20250331 Operating Expenses 8680000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Operating Expenses 162000.0000 USD 1 us-gaap/2024 Business Segments= Securities; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Expenses 3493000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Operating Income Loss -60000.0000 USD 1 us-gaap/2024 Business Segments= Direct Marketing Online Sales; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Operating Income Loss -4680000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Income Loss -638000.0000 USD 1 us-gaap/2024 Business Segments= Securities; Consolidation Items= Operating Segments;
0001641172-25-010712 20241231 Other Investments 500000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Other Nonoperating Income Expense 21000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Other Nonoperating Income Expense -902000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Other Nonoperating Income Expense 4000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20211031 Payments To Acquire Property Plant And Equipment 1500000.0000 USD 0 us-gaap/2024 Legal Entity= Pinnacle Bank; Property Plant And Equipment By Type= Site Improvements; Type Of Arrangement= Life Care Agreement;
0001641172-25-010712 20220331 Payments To Acquire Property Plant And Equipment 3200000.0000 USD 0 us-gaap/2024 Debt Instrument= Pinnacle Loan; Property Plant And Equipment By Type= Facility;
0001641172-25-010712 20220331 Payments To Acquire Property Plant And Equipment 1000000.0000 USD 0 us-gaap/2024 Debt Instrument= Pinnacle Loan; Property Plant And Equipment By Type= Land;
0001641172-25-010712 20250331 Preferred Stock Liquidation Preference Value 0.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Preferred Stock Par Or Stated Value Per Share 0.0200 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Preferred Stock Value USD 0 us-gaap/2024
0001641172-25-010712 20240331 Proceeds From Repayment Of Investments -31000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Proceeds From Sale And Maturity Of Marketable Securities 2806000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Proceeds From Sale Of Notes Receivable 3971000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Profit Loss -4072000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0001641172-25-010712 20241231 Property Plant And Equipment Net 5381000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 2000.0000 USD 1 us-gaap/2024 Business Segments= Biotechnology; Product Or Service= Rental Internet Sales;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 3871000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 3073000.0000 USD 1 us-gaap/2024 Product Or Service= Printed Products;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 135000.0000 USD 1 us-gaap/2024 Business Segments= Commercialand Security Printing; Product Or Service= Printed Products Revenue;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 4954000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 714000.0000 USD 1 us-gaap/2024 Product Or Service= Rental Income;
0001641172-25-010712 20250331 Stock Based Payments For Professional Services 29000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 83213000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -256176000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-010712 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 18249000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001641172-25-010712 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 32716000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest USD 0 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20250331 Stock Issued During Period Value Other 850000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-010712 20241231 Accounts Receivable Net Current 3068000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20230430 Common Stock Shares Authorized 4000000000.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20231031 Common Stock Shares Authorized 60496041.0000 shares 0 us-gaap/2024 Equity Components= Common Stock; Legal Entity= D S S Bio Health Securities Inc;
0001641172-25-010712 20240930 Common Stock Shares Issued 11503955.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20241231 Common Stock Shares Issued 8092518.0000 shares 0 us-gaap/2024
0001641172-25-010712 20230430 Common Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20231231 Common Stock Shares Outstanding 140264240.0000 shares 0 us-gaap/2024
0001641172-25-010712 20231231 Common Stock Shares Outstanding 10000000.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20240331 Gain Loss On Investments -189000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Gain Loss On Sale Of Real Estate -250000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -458000.0000 USD 1 us-gaap/2024 Business Segments= Product Packaging; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -5084000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Income Loss From Discontinued Operations Net Of Tax Per Basic Share -0.5800 USD 1 us-gaap/2024
0001641172-25-010712 20241231 Prepaid Expense And Other Assets Current 1141000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Accounts Payable Current 2431000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Accrued Interest On Notes Payable USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Accrued Interest On Notes Payable 985000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Assets 92435000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations -456000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20241231 Commitments And Contingencies 0.0000 USD 0 us-gaap/2024 Type Of Arrangement= License Agreement;
0001641172-25-010712 20241231 Common Stock Par Or Stated Value Per Share 0.0200 USD 0 us-gaap/2024
0001641172-25-010712 20221231 Common Stock Shares Issued 3877282251.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical; ImpactBioMedical
0001641172-25-010712 20230430 Common Stock Shares Issued 0.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20250331 Common Stock Shares Issued 9092518.0000 shares 0 us-gaap/2024
0001641172-25-010712 20250331 Common Stock Shares Outstanding 9092518.0000 shares 0 us-gaap/2024
0001641172-25-010712 20241231 Equity Method Investments 129000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Gain Loss On Sale Of Real Estate USD 1 0001641172-25-010712
0001641172-25-010712 20241231 Goodwill 1769000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Goodwill 25093000.0000 USD 0 us-gaap/2024 Legal Entity= Impact Bio Medical; ImpactBioMedical
0001641172-25-010712 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -270000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Income Loss From Discontinued Operations Net Of Tax Per Basic Share -0.5500 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Increase Decrease In Accounts Payable 430000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Increase Decrease In Other Operating Liabilities -51000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Issuance Of Common Stock Net Of Expenses To Subsidiary 1500000.0000 USD 1 0001641172-25-010712
0001641172-25-010712 20250331 Issuance Of Common Stock Net Of Expenses To Subsidiary USD 1 0001641172-25-010712 Equity Components= Retained Earnings;
0001641172-25-010712 20250331 Long Term Debt Current 485000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-010712 20241231 Long Term Debt Noncurrent 2398000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Marketable Securities Noncurrent 9211000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Net Cash Provided By Used In Operating Activities -1638000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Notes And Loans Receivable Net Current 5544000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note One;
0001641172-25-010712 20250331 Notes And Loans Receivable Net Noncurrent 66000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-010712 20250331 Notes And Loans Receivable Net Noncurrent 135000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Note Thirteen;
0001641172-25-010712 20240331 Operating Expenses 1124000.0000 USD 1 us-gaap/2024 Business Segments= Securities; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Expenses 34000.0000 USD 1 us-gaap/2024 Business Segments= Direct Marketing Online Sales; Consolidation Items= Operating Segments;
0001641172-25-010712 20240331 Operating Income Loss -481000.0000 USD 1 us-gaap/2024 Business Segments= Commercial Lending; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Operating Income Loss -3726000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Operating Lease Liability Noncurrent 6168000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20241231 Other Intangible Assets Net 18890000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20240331 Other Nonoperating Income Expense -9000.0000 USD 1 us-gaap/2024 Business Segments= Direct Marketing Online Sales; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Other Nonoperating Income Expense 7000.0000 USD 1 us-gaap/2024 Business Segments= Direct Marketing Online Sales; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Other Nonoperating Income Expense -1077000.0000 USD 1 us-gaap/2024 Business Segments= Securities; Consolidation Items= Operating Segments;
0001641172-25-010712 20211031 Payments To Acquire Property Plant And Equipment 32100000.0000 USD 0 us-gaap/2024 Legal Entity= Pinnacle Bank; Property Plant And Equipment By Type= Facility; Type Of Arrangement= Life Care Agreement;
0001641172-25-010712 20250331 Preferred Stock Liquidation Preference 1000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20230430 Preferred Stock Shares Authorized 100000000.0000 shares 0 us-gaap/2024 Legal Entity= Impact Bio Medical Inc; ImpactBioMedicalInc
0001641172-25-010712 20241231 Preferred Stock Shares Authorized 47000.0000 shares 0 us-gaap/2024
0001641172-25-010712 20250331 Proceeds From Issuance Of Long Term Debt 109000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Profit Loss -5109000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Profit Loss USD 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20240331 Profit Loss USD 1 us-gaap/2024 Equity Components= Preferred Stock;
0001641172-25-010712 20250331 Profit Loss -5296000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Profit Loss USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-010712 20250331 Profit Loss -4777000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-010712 20240331 Revenue From Contract With Customer Excluding Assessed Tax 3080000.0000 USD 1 us-gaap/2024 Business Segments= Product Packaging; Consolidation Items= Operating Segments;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 221000.0000 USD 1 us-gaap/2024 Business Segments= Securities Revenue; Product Or Service= Commission Income;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 699000.0000 USD 1 us-gaap/2024 Business Segments= Securities Revenue; Product Or Service= Rental Income;
0001641172-25-010712 20250331 Revenue From Contract With Customer Excluding Assessed Tax 3998000.0000 USD 1 us-gaap/2024 Product Or Service= Printed Products Revenue;
0001641172-25-010712 20240331 Selling General And Administrative Expense 3561000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20250331 Shares Outstanding 9092518.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 63927000.0000 USD 0 us-gaap/2024 Equity Components= Parent;
0001641172-25-010712 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 29821000.0000 USD 0 us-gaap/2024
0001641172-25-010712 20250331 Stock Issued During Period Shares Share Based Compensation shares 1 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-010712 20250331 Stock Issued During Period Value Other 870000.0000 USD 1 us-gaap/2024
0001641172-25-010712 20240331 Weighted Average Number Of Diluted Shares Outstanding 7066772.0000 shares 1 us-gaap/2024

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Increase Decrease In Accounts Receivable us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Proceeds From Issuance Of Long Term Debt us-gaap/2024 0 0 monetary D D Proceeds from Issuance of Long-Term Debt The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Operating Lease Liability Current us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Current Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 0 0 monetary D C Revenue from Contract with Customer, Excluding Assessed Tax Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Gain Loss On Investments us-gaap/2024 0 0 monetary D C Gain (Loss) on Investments Amount of realized and unrealized gain (loss) on investment.
Depreciation And Amortization us-gaap/2024 0 0 monetary D D Depreciation, Depletion and Amortization, Nonproduction The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary I C Equity, Including Portion Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D D Net Income (Loss) Attributable to Noncontrolling Interest Amount of Net Income (Loss) attributable to noncontrolling interest.
Preferred Stock Liquidation Preference Value us-gaap/2024 0 0 monetary I C Preferred Stock, Liquidation Preference, Value Value of the difference between preference in liquidation and the par or stated values of the preferred shares.
Real Estate Assets Held For Development And Sale us-gaap/2024 0 0 monetary I D Real Estate Assets Held for Development and Sale For banks, the total amount of real estate assets held for development and sale.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Stock Issued During Period Shares Issued For Services us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Issued for Services Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Impairment Of Notes Receivable 0001641172-25-010712 1 0 monetary D D Impairment of notes receivable Impairment of notes receivable.
Proceeds From Repayment Of Investments 0001641172-25-010712 1 0 monetary D D Purchase of investment Proceeds from repayment of investments.
Accounts Receivable Net Current us-gaap/2024 0 0 monetary I D Accounts Receivable, after Allowance for Credit Loss, Current Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Additional Paid In Capital us-gaap/2024 0 0 monetary I C Additional Paid in Capital Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Accrued Interest On Notes Payable 0001641172-25-010712 1 0 monetary D D Accrued interest on notes payable Accrued interest on notes payable.
Restricted Cash Current us-gaap/2024 0 0 monetary I D Restricted Cash, Current Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Change In Right Of Use Assets 0001641172-25-010712 1 0 monetary D C ChangeInRightOfUseAssets Change in right of use assets.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Interest Expense us-gaap/2024 0 0 monetary D D Interest Expense, Operating and Nonoperating Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.
Operating Lease Right Of Use Asset us-gaap/2024 0 0 monetary I D Operating Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating lease.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Gain Loss On Sale Of Real Estate 0001641172-25-010712 1 0 monetary D C Gain loss on sale of real estate Gain loss on sale of real estate.
Provision For Loan Loss Recoveries 0001641172-25-010712 1 0 monetary D C Provision for loan loss recoveries Provision for loan loss recoveries.
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share us-gaap/2024 0 0 perShare D Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
Increase Decrease In Other Operating Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Other Operating Assets Amount of increase (decrease) in operating assets classified as other.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Preferred Stock Shares Issued us-gaap/2024 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Proceeds From Sale And Maturity Of Marketable Securities us-gaap/2024 0 0 monetary D D Proceeds from Sale and Maturity of Marketable Securities The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
Repayments Of Long Term Debt us-gaap/2024 0 0 monetary D C Repayments of Long-Term Debt The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
Accrued Expenses And Deferred Revenue Current 0001641172-25-010712 1 0 monetary I C Accrued expenses and deferred revenue Accrued expenses and deferred revenue current.
Selling General And Administrative Expense us-gaap/2024 0 0 monetary D D Selling, General and Administrative Expense The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Stock Issued During Period Value Issued For Services us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Issued for Services Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
Proceeds From Sale Of Investment Related Party 0001641172-25-010712 1 0 monetary D D Sale of investment, related party Proceeds from sale of investment related party.
Stock Based Payments For Professional Services 0001641172-25-010712 1 0 monetary D D Stock based payments for professional services Stock based payments for professional services.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from change in exchange rate. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalents include, but are not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
Increase Decrease In Inventories us-gaap/2024 0 0 monetary D C Increase (Decrease) in Inventories The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Equity Method Investments us-gaap/2024 0 0 monetary I D Equity Method Investments This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.
Increase Decrease In Other Operating Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Other Operating Liabilities Amount of increase (decrease) in operating liabilities classified as other.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Preferred Stock Value us-gaap/2024 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Other Liabilities Current us-gaap/2024 0 0 monetary I C Other Liabilities, Current Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
Goodwill us-gaap/2024 0 0 monetary I D Goodwill Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Profit Loss us-gaap/2024 0 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
Current Portion Of Longterm Debt On Assets Heldforsale Net 0001641172-25-010712 1 0 monetary I C Current portion of long-term debt on assets held-for-sale, net Current portion of long term debt on assets held for sale net.
Issuance Of Common Stock Net Of Expenses To Subsidiary 0001641172-25-010712 1 0 monetary D C Issuance of common stock, net of expenses - Impact BioMedical, Inc. Issuance of common stock net of expenses to subsidiary.
Provision For Loan Losses 0001641172-25-010712 1 0 monetary D C Provision for loan losses Provision for loan losses.
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Operating Expenses us-gaap/2024 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Prepaid Expense And Other Assets Current us-gaap/2024 0 0 monetary I D Prepaid Expense and Other Assets, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
Proceeds From Sale Of Notes Receivable us-gaap/2024 0 0 monetary D D Proceeds from Sale of Notes Receivable The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.
Stock Issued During Period Shares Other us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Other Number of shares of stock issued attributable to transactions classified as other.
Repayments On Margin Loans 0001641172-25-010712 1 0 monetary D C Repayments on margin loans Repayments on margin loans.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Income Loss From Equity Method Investments us-gaap/2024 0 0 monetary D C Income (Loss) from Equity Method Investments Amount of income (loss) for proportionate share of equity method investee's income (loss).
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Other Intangible Assets Net us-gaap/2024 0 0 monetary I D Other Intangible Assets, Net Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.
Marketable Securities Noncurrent us-gaap/2024 0 0 monetary I D Marketable Securities, Noncurrent Amount of investment in marketable security, classified as noncurrent.
Notes And Loans Receivable Net Noncurrent us-gaap/2024 0 0 monetary I D Financing Receivable, after Allowance for Credit Loss, Noncurrent Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Income Loss From Discontinued Operations Net Of Tax Per Basic Share us-gaap/2024 0 0 perShare D Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
Increase Decrease In Accounts Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
Increase Decrease In Operating Lease Liability us-gaap/2024 0 0 monetary D D Increase (Decrease) in Operating Lease Liability Amount of increase (decrease) in obligation for operating lease.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Net Income Loss Available To Common Stockholders Basic us-gaap/2024 0 0 monetary D C Net Income (Loss) Available to Common Stockholders, Basic Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
Operating Costs And Expenses us-gaap/2024 0 0 monetary D D Operating Costs and Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.
Preferred Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Shares Outstanding us-gaap/2024 0 0 shares I Shares, Outstanding Number of shares issued which are neither cancelled nor held in the treasury.
Change In Inventory Obsolescence 0001641172-25-010712 1 0 monetary D C Change in inventory obsolescence Change in inventory obsolescence.
Gains Losses On Sales Of Real Estate 0001641172-25-010712 1 0 monetary D C Loss on sale of real estate Gains losses on sales of real estate.
Issuance Of Common Stock For Bonus 0001641172-25-010712 1 0 monetary D D Issuance of common stock for bonus Issuance of common stock for bonus.
Gain Loss On Sale Of Investments us-gaap/2024 0 0 monetary D C Gain (Loss) on Sale of Investments The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.
Investment Income Interest us-gaap/2024 0 0 monetary D C Investment Income, Interest Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Other Investments us-gaap/2024 0 0 monetary I D Other Investments Amount of investments classified as other.
Other Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Other Nonoperating Income (Expense) Amount of income (expense) related to nonoperating activities, classified as other.
Preferred Stock Shares Authorized us-gaap/2024 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2024 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Equity Method Investments Gain Loss 0001641172-25-010712 1 0 monetary D C EquityMethodInvestmentsGainLoss Equity method investments gain loss.
Increase Decrease In Accrued Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accrued Liabilities The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
Long Term Debt Current us-gaap/2024 0 0 monetary I C Long-Term Debt, Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.
Long Term Debt Noncurrent us-gaap/2024 0 0 monetary I C Long-Term Debt, Excluding Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.
Minority Interest us-gaap/2024 0 0 monetary I C Equity, Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
Notes And Loans Receivable Net Current us-gaap/2024 0 0 monetary I D Financing Receivable, after Allowance for Credit Loss, Current Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.
Operating Lease Liability Noncurrent us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Noncurrent Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Preferred Stock Liquidation Preference us-gaap/2024 0 0 perShare I Preferred Stock, Liquidation Preference Per Share The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Stock Issued During Period Shares Share Based Compensation us-gaap/2024 0 0 shares D Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
Stock Issued During Period Value Other us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Other Value of shares of stock issued attributable to transactions classified as other.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Increase Decrease Assets Held For Sale 0001641172-25-010712 1 0 monetary D C Increase decrease assets held for sale Increase decrease assets held for sale.
Proceed From Sale Of Real Estate 0001641172-25-010712 1 0 monetary D D Sale of real estate Proceed from sale of real estate.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001641172-25-010712 2 9 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0001641172-25-010712 2 10 BS 0 H Restricted Cash Current us-gaap/2024 Restricted cash 0
0001641172-25-010712 2 11 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable, net 0
0001641172-25-010712 2 12 BS 0 H Inventory Net us-gaap/2024 Inventory, net 0
0001641172-25-010712 2 13 BS 0 H Real Estate Assets Held For Development And Sale us-gaap/2024 Assets held for sale 0
0001641172-25-010712 2 14 BS 0 H Notes And Loans Receivable Net Current us-gaap/2024 Current portion of notes receivable 0
0001641172-25-010712 2 15 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2024 Prepaid expenses and other current assets 0
0001641172-25-010712 2 16 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0001641172-25-010712 2 17 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property, plant and equipment, net 0
0001641172-25-010712 2 18 BS 0 H Other Investments us-gaap/2024 Other investments 0
0001641172-25-010712 2 19 BS 0 H Equity Method Investments us-gaap/2024 Investment, equity method 0
0001641172-25-010712 2 20 BS 0 H Marketable Securities Noncurrent us-gaap/2024 Marketable securities 0
0001641172-25-010712 2 21 BS 0 H Notes And Loans Receivable Net Noncurrent us-gaap/2024 Notes receivable 0
0001641172-25-010712 2 22 BS 0 H Other Assets Noncurrent us-gaap/2024 Other assets 0
0001641172-25-010712 2 23 BS 0 H Operating Lease Right Of Use Asset us-gaap/2024 Right-of-use assets 0
0001641172-25-010712 2 24 BS 0 H Goodwill us-gaap/2024 Goodwill 0
0001641172-25-010712 2 25 BS 0 H Other Intangible Assets Net us-gaap/2024 Other intangible assets, net 0
0001641172-25-010712 2 26 BS 0 H Assets us-gaap/2024 Total assets 0
0001641172-25-010712 2 29 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0001641172-25-010712 2 30 BS 0 H Accrued Expenses And Deferred Revenue Current 0001641172-25-010712 Accrued expenses and deferred revenue 0
0001641172-25-010712 2 31 BS 0 H Other Liabilities Current us-gaap/2024 Other current liabilities 0
0001641172-25-010712 2 32 BS 0 H Operating Lease Liability Current us-gaap/2024 Current portion of lease liability 0
0001641172-25-010712 2 33 BS 0 H Long Term Debt Current us-gaap/2024 Current portion of long-term debt 0
0001641172-25-010712 2 34 BS 0 H Current Portion Of Longterm Debt On Assets Heldforsale Net 0001641172-25-010712 Current portion of long-term debt on assets held-for-sale, net 0
0001641172-25-010712 2 35 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0001641172-25-010712 2 36 BS 0 H Long Term Debt Noncurrent us-gaap/2024 Long-term debt, net 0
0001641172-25-010712 2 37 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Long term lease liability 0
0001641172-25-010712 2 38 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0001641172-25-010712 2 39 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingencies (Note 11) 0
0001641172-25-010712 2 41 BS 0 H Preferred Stock Value us-gaap/2024 Preferred stock, $.02 par value; 47,000 shares authorized, zero shares issued and outstanding (zero on December 31, 2024); Liquidation value $1,000 per share, zero aggregate. zero on December 31, 2024). 0
0001641172-25-010712 2 42 BS 0 H Common Stock Value us-gaap/2024 Common stock, $.02 par value; 200,000,000 shares authorized, 9,092,518 shares issued and outstanding (8,092,518 on December 31, 2024) 0
0001641172-25-010712 2 43 BS 0 H Additional Paid In Capital us-gaap/2024 Additional paid-in capital 0
0001641172-25-010712 2 44 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0001641172-25-010712 2 45 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders equity of the Company 0
0001641172-25-010712 2 46 BS 0 H Minority Interest us-gaap/2024 Non-controlling interest in subsidiaries 0
0001641172-25-010712 2 47 BS 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Total stockholders equity 0
0001641172-25-010712 2 48 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and stockholders equity 0
0001641172-25-010712 3 1 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock, par value 0
0001641172-25-010712 3 2 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized 0
0001641172-25-010712 3 3 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued 0
0001641172-25-010712 3 4 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding 0
0001641172-25-010712 3 5 BS 1 H Preferred Stock Liquidation Preference us-gaap/2024 Preferred stock, liquidation preference per share 0
0001641172-25-010712 3 6 BS 1 H Preferred Stock Liquidation Preference Value us-gaap/2024 Preferred stock, liquidation preference 0
0001641172-25-010712 3 7 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value 0
0001641172-25-010712 3 8 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized 0
0001641172-25-010712 3 9 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued 0
0001641172-25-010712 3 10 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding 0
0001641172-25-010712 4 9 IS 0 H Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 Total revenue 0
0001641172-25-010712 4 11 IS 0 H Operating Costs And Expenses us-gaap/2024 Cost of revenue 0
0001641172-25-010712 4 12 IS 0 H Selling General And Administrative Expense us-gaap/2024 Selling, general and administrative (including stock based compensation) 0
0001641172-25-010712 4 13 IS 0 H Operating Expenses us-gaap/2024 Total costs and expenses 0
0001641172-25-010712 4 14 IS 0 H Operating Income Loss us-gaap/2024 Operating loss 0
0001641172-25-010712 4 16 IS 0 H Investment Income Interest us-gaap/2024 Interest income 0
0001641172-25-010712 4 17 IS 0 H Other Nonoperating Income Expense us-gaap/2024 Other income 0
0001641172-25-010712 4 18 IS 0 H Interest Expense us-gaap/2024 Interest expense 1
0001641172-25-010712 4 19 IS 0 H Income Loss From Equity Method Investments us-gaap/2024 Loss on equity method investment 0
0001641172-25-010712 4 20 IS 0 H Gain Loss On Investments us-gaap/2024 Loss on investments 0
0001641172-25-010712 4 21 IS 0 H Provision For Loan Losses 0001641172-25-010712 Provision for loan losses 0
0001641172-25-010712 4 22 IS 0 H Gains Losses On Sales Of Real Estate 0001641172-25-010712 Loss on sale of real estate 0
0001641172-25-010712 4 23 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Loss from operations before income taxes 0
0001641172-25-010712 4 24 IS 0 H Income Tax Expense Benefit us-gaap/2024 Income tax benefit (expense) 1
0001641172-25-010712 4 25 IS 0 H Profit Loss us-gaap/2024 Net loss 0
0001641172-25-010712 4 26 IS 0 H Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 Loss from operations attributed to noncontrolling interest 1
0001641172-25-010712 4 27 IS 0 H Net Income Loss Available To Common Stockholders Basic us-gaap/2024 Net loss attributable to DSS common stockholders 0
0001641172-25-010712 4 29 IS 0 H Income Loss From Discontinued Operations Net Of Tax Per Basic Share us-gaap/2024 Basic 0
0001641172-25-010712 4 30 IS 0 H Income Loss From Discontinued Operations Net Of Tax Per Diluted Share us-gaap/2024 Diluted 0
0001641172-25-010712 4 32 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Basic 0
0001641172-25-010712 4 33 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Diluted 0
0001641172-25-010712 5 2 CF 0 H Profit Loss us-gaap/2024 Net loss 0
0001641172-25-010712 5 4 CF 0 H Depreciation And Amortization us-gaap/2024 Depreciation and amortization 0
0001641172-25-010712 5 5 CF 0 H Share Based Compensation us-gaap/2024 Stock based compensation 0
0001641172-25-010712 5 6 CF 0 H Issuance Of Common Stock For Bonus 0001641172-25-010712 Issuance of common stock for bonus 0
0001641172-25-010712 5 7 CF 0 H Stock Based Payments For Professional Services 0001641172-25-010712 Stock based payments for professional services 0
0001641172-25-010712 5 8 CF 0 H Equity Method Investments Gain Loss 0001641172-25-010712 Loss on equity method investment 1
0001641172-25-010712 5 9 CF 0 H Gain Loss On Sale Of Investments us-gaap/2024 Loss on investments 1
0001641172-25-010712 5 10 CF 0 H Gain Loss On Sale Of Real Estate 0001641172-25-010712 Loss on sale of real estate 1
0001641172-25-010712 5 11 CF 0 H Change In Right Of Use Assets 0001641172-25-010712 Change in ROU assets 1
0001641172-25-010712 5 12 CF 0 H Change In Inventory Obsolescence 0001641172-25-010712 Change in inventory obsolescence 1
0001641172-25-010712 5 13 CF 0 H Accrued Interest On Notes Payable 0001641172-25-010712 Accrued interest on notes payable 0
0001641172-25-010712 5 14 CF 0 H Provision For Loan Loss Recoveries 0001641172-25-010712 Provision for loan loss recoveries 1
0001641172-25-010712 5 15 CF 0 H Impairment Of Notes Receivable 0001641172-25-010712 Impairment of notes receivable 0
0001641172-25-010712 5 17 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Accounts receivable 1
0001641172-25-010712 5 18 CF 0 H Increase Decrease In Inventories us-gaap/2024 Inventory 1
0001641172-25-010712 5 19 CF 0 H Increase Decrease Assets Held For Sale 0001641172-25-010712 Assets held for sale 1
0001641172-25-010712 5 20 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Prepaid expenses and other current assets 1
0001641172-25-010712 5 21 CF 0 H Increase Decrease In Other Operating Assets us-gaap/2024 Other assets 1
0001641172-25-010712 5 23 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Accounts payable 0
0001641172-25-010712 5 24 CF 0 H Increase Decrease In Accrued Liabilities us-gaap/2024 Accrued expenses 0
0001641172-25-010712 5 25 CF 0 H Increase Decrease In Operating Lease Liability us-gaap/2024 Change in ROU liabilities 0
0001641172-25-010712 5 26 CF 0 H Increase Decrease In Other Operating Liabilities us-gaap/2024 Other liabilities 0
0001641172-25-010712 5 27 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash used by operating activities 0
0001641172-25-010712 5 29 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Purchase of property, plant and equipment 1
0001641172-25-010712 5 30 CF 0 H Proceed From Sale Of Real Estate 0001641172-25-010712 Sale of real estate 0
0001641172-25-010712 5 31 CF 0 H Proceeds From Repayment Of Investments 0001641172-25-010712 Purchase of investment 0
0001641172-25-010712 5 32 CF 0 H Proceeds From Sale Of Investment Related Party 0001641172-25-010712 Sale of investment, related party 0
0001641172-25-010712 5 33 CF 0 H Proceeds From Sale And Maturity Of Marketable Securities us-gaap/2024 Sale of marketable securities 0
0001641172-25-010712 5 34 CF 0 H Proceeds From Sale Of Notes Receivable us-gaap/2024 Payments received on notes receivable 0
0001641172-25-010712 5 35 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash provided by investing activities 0
0001641172-25-010712 5 37 CF 0 H Repayments Of Long Term Debt us-gaap/2024 Payments of long-term debt 1
0001641172-25-010712 5 38 CF 0 H Repayments On Margin Loans 0001641172-25-010712 Payments on margin loans 1
0001641172-25-010712 5 39 CF 0 H Proceeds From Issuance Of Long Term Debt us-gaap/2024 Borrowings of long-term debt 0
0001641172-25-010712 5 40 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash used by financing activities 0
0001641172-25-010712 5 41 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations us-gaap/2024 Net increase (decrease) in cash 0
0001641172-25-010712 5 42 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash and cash equivalents at beginning of period 0
0001641172-25-010712 5 43 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2024 Cash and cash equivalents and restricted cash at end of period 0
0001641172-25-010712 6 11 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Balance 0
0001641172-25-010712 6 12 EQ 0 H Shares Outstanding us-gaap/2024 Balance, shares 0
0001641172-25-010712 6 13 EQ 0 H Profit Loss us-gaap/2024 Net loss 0
0001641172-25-010712 6 14 EQ 0 H Issuance Of Common Stock Net Of Expenses To Subsidiary 0001641172-25-010712 Issuance of common stock, net of expenses - Impact BioMedical, Inc. 0
0001641172-25-010712 6 15 EQ 0 H Stock Issued During Period Value Other us-gaap/2024 Issuance of common stock for bonus 0
0001641172-25-010712 6 16 EQ 0 H Stock Issued During Period Shares Other us-gaap/2024 Issuance of common stock for bonus, shares 0
0001641172-25-010712 6 17 EQ 0 H Stock Issued During Period Value Issued For Services us-gaap/2024 Stock based payments for professional services rendered 0
0001641172-25-010712 6 18 EQ 0 H Stock Issued During Period Shares Issued For Services us-gaap/2024 Stock based payments for professional services rendered, shares 0
0001641172-25-010712 6 19 EQ 0 H Stock Issued During Period Shares Share Based Compensation us-gaap/2024 Stock based payments 0
0001641172-25-010712 6 20 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Balance 0
0001641172-25-010712 6 21 EQ 0 H Shares Outstanding us-gaap/2024 Balance, shares 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.